Pascal Biosciences
  • Home
  • Company
    • About
    • Leadership
    • Board of Directors
  • Programs
    • Overview
    • Cannabinoid therapeutic for treating COVID-19
    • PAS-403 for Glioblastoma
    • PAS-393 for Cancer
    • Research: Pre-BCR antibody for Leukemia
  • News
  • Investors
  • Contact
Skip to content
Home / Karoly Nikolich, PhD

News

17Jan 2019

Karoly Nikolich, PhD

  • Jan 17, 2019

Recent Posts

  • Pascal Biosciences Appoints Mark van der Horst as Vice President of Corporate Communications
  • Pascal Announces Non-Brokered Private Placement
  • Pascal Announces Re-pricing of Shares for Debt Settlement
  • Pascal Biosciences Confirms Specific Cannabinoids Combat Coronavirus
  • Pascal Biosciences to Present at International Cannabinoid Derived Pharmaceutical Summit

Categories

  • In the News
  • Press Releases
  • Uncategorized

Archives

  • November 2020
  • September 2020
  • August 2020
  • July 2020
  • May 2020
  • March 2020
  • October 2019
  • September 2019
  • May 2019
  • April 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • July 2018
  • June 2018
  • February 2018
  • December 2017
  • September 2017
  • May 2017
  • March 2017
  • November 2016
  • October 2016
  • September 2016

About

Pascal Biosciences Inc. (TSX-V: PAS, FSE:6PB.F) is a biotechnology company focused on developing cannabinoid-based and targeted therapeutics to fight cancer.

Locations

USA

Fluke Hall, Suite 304
Box 352141
4000 Mason Road
Seattle, WA 98195-2141

Canada

280 7th Avenue East
Vancouver, BC V5T 0B4

Contact

Phone

206.221.3443

Email

info@pascalbiosciences.com

Investors

invest@pascalbiosciences.com

Partnering & Business Development

bd@pascalbiosciences.com

Let's Connect

  • Facebook
  • Twitter
  • Linked
  • Home
  • Company
  • Programs
  • News
  • Investors
  • Contact
  • Disclaimer

© Copyright 2020 Pascal Biosciences Inc. All rights reserved.   Seattle Website Design by Jordan Crown Design

  • Home
  • Company
    • About
    • Leadership
    • Board of Directors
  • Programs
    • Overview
    • Cannabinoid therapeutic for treating COVID-19
    • PAS-403 for Glioblastoma
    • PAS-393 for Cancer
    • Research: Pre-BCR antibody for Leukemia
  • News
  • Investors
  • Contact

‹ › ×